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Infections with the hepatitis C virus (HCV) are a major cause of
chronic liver disease. While the acute phase of infection is mostly
asymptomatic, this virus has the high propensity to establish per-
sistence and in the course of one to several decades liver disease
can develop. HCV is a paradigm for the complex interplay
between the interferon (IFN) system and viral countermeasures.
The virus induces an IFN response within the infected cell and
is rather sensitive against the antiviral state triggered by IFNs,
yet in most cases HCV persists. Numerous IFN-stimulated genes
(ISGs) have been reported to suppress HCV replication, but in
only a few cases we begin to understand the molecular mecha-
nisms underlying antiviral activity. It is becoming increasingly
clear that blockage of viral replication is mediated by the con-
certed action of multiple ISGs that target different steps of the
HCV replication cycle. This review brieﬂy summarizes the activa-
tion of the IFN system by HCV and then focuses on ISGs targeting
the HCV replication cycle and their possible mode of action.
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V.
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The hepatitis C virus (HCV) is a member of the Flaviviridae family
where it forms the genus hepacivirus. These members have in
common a single stranded RNA genome of positive polarity and
an enveloped virus particle. Seven HCV genotypes (1–7), in most
cases with numerous subtypes (a, b etc.), are distinguished, dif-
fering in their nucleotide sequence by 33% and 25%, respectively
[1]. HCV infects only humans and chimpanzees. This narrow host
range is due to species-speciﬁc host cell factors promoting or
restricting HCV replication [2].
Around 2% of the world population is chronically infected with
HCV [3] and these people are at high risk to develop liver diseases.
Treatment of hepatitis C to the most part depends on pegylatedJournal of Hepatology 20
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 These authors contributed equally to this work.interferon-alpha (pegIFN-a) and ribavirin. A successful therapy is
determined by multiple parameters such as age and sex of the
patient, duration and degree of liver damage, co-infection with
other viruses (e.g., HIV) and alcohol consumption. However, the
most important predictors of treatment outcome are distinct
genetic polymorphisms in the interleukin (IL)28B gene locus
[4,5] and the genotype of the infecting virus. More than 80% of
the individuals infected with genotype 2 or 3 viruses, but only
45% of genotype 1-infected individuals, achieve sustained viral
responsewith this treatment regimen. In the latter case, this num-
ber has increased to75%with the recent implementation of a tri-
ple combination therapy, composed of pegIFN-a, ribavirin, and a
direct-acting antiviral (DAAs) targeting the HCV protease that
resides in non-structural protein 3 (NS3) [6,7]. However, this ther-
apy has serious side effects, is very costly and still depends on the
individual patient response to pegIFN-a and ribavirin as deduced
from the fact that in treatment-experienced patients, response
rates are higher among previous relapsers as compared to patients
with a previous breakthrough or non-response [8].
The possibility to propagate HCV in cultured hepatoma cells
and the recent availability of cell systems based on immortalized
and primary human hepatocytes (PHHs) provided important
insights into induction of innate antiviral defense by HCV and
viral countermeasures [9]. Moreover, complementing studies
with human liver samples have become available [10–12]. The
common denominator is that HCV induces an innate antiviral
response that suppresses virus replication. However, the mecha-
nisms by which HCV replication is suppressed are poorly under-
stood. In this review, we will brieﬂy summarize how HCV is
sensed in the infected cell and how this leads to the activation
of the IFN system. Further, we will focus on ISGs and their role
in controlling HCV replication, emphasizing those ISGs for which
we begin to understand the molecular mechanisms responsible
for replication suppression. We will not cover the clinical impli-
cations of the IFN response with respect to antiviral therapy or
pathogenesis of liver disease as these topics have been covered
in excellent recent reviews [5,13,14].Detection of invading hepatitis C virus
Hepatitis C virus detection by RIG-I-like receptors
The innate immune system comprises several pathogen recogni-
tion receptors (PRRs) (Fig. 1). In case of viral infections, major key13 vol. 59 j 1331–1341
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players are the Toll-like receptor (TLR) family and the RIG-I-like
receptors (RLRs). Three proteins belong to the latter: retinoic acid
inducible gene-I (RIG-I), melanoma differentiation associated
gene 5 (MDA5, IFIH1) and laboratory of genetics and physiology
2 (LGP2, DHX58). Upon stimulation, RIG-I as well as MDA5 acti-
vate mitochondrial antiviral-signaling protein (MAVS, IPS-1, Car-
dif, VISA) located at mitochondria, peroxisomes and
mitochondria-associated membranes (MAMs) [15,16] (Fig. 1).
Activation of MAVS leads to phosphorylation of IFN regulatory
factor 3 (IRF3) and IRF7. They are translocated into the nucleus
to stimulate transcription of IFN-b and several ISGs.
RIG-I preferentially senses short dsRNA molecules with 50-
triphosphorylated RNA [17–20] whereas MDA5 appears to sense
long dsRNA independent of a 50-triphosphorylated end [17]. In
agreement with this speciﬁcity, RIG-I seems to be the key sensor
of HCV RNA, with the poly(U/UC) tract in the 30 non-translated
region of the HCV genome playing an important role [21,22]. In
fact, mouse embryonic ﬁbroblasts (MEFs) from RIG-I/ mice
stimulated with HCV RNA do not produce IFN [21] and analogousSR-B1
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Fig. 1. IFN signaling pathways. Simpliﬁed schematic representation of major sensor pa
Viral RNA is detected by PRRs, such as TLR3 residing in the endosome (ES), or by
phosphorylation and dimerization of IRF3 that translocates into the nucleus to stimulat
cytokines. Secreted IFNs bind to their cognate receptor, thus activating the JAK/STAT pat
into the nucleus to induce expression of further ISGs and IFN genes. A subset of these ISGs
most notably MAVS and TRIF that are cleaved by the NS3/4A protease. Additionally, core
reticulum; MAM, mitochondrion-associated membrane.
1332 Journal of Hepatology 2013results were obtained with HuH7-derived human hepatoma cell
lines as well as PHHs with attenuated RIG-I expression [23,24].
Whether MDA5 can detect invading HCV remains to be clari-
ﬁed. One study reported suppression of HCV in vitro upon overex-
pression of MDA5 [25]. Moreover, HCV replication is enhanced in
cells expressing the V protein of paramyxovirus, which is a
known inhibitor of MDA5 [26,27]. However, inhibition of STAT1
(signal transducer and activator of transcription1), rather than
MDA5, by the V protein might account for increased HCV replica-
tion [28,29]. While other members of the Flaviviridae family are
detected by both RIG-I and MDA5 [30], the observation that
MDA5/ MEFs still produce IFN-b upon stimulation with HCV
RNA [21] suggests that RIG-I is the key player in detecting HCV.
Hepatitis C virus detection by Toll-like receptors
TLRs are membrane-bound receptors that detect invading patho-
gens either on the plasma membrane or in endosomes (Fig. 1). In
case of HCV, TLR3 and TLR7 that recognize dsRNA and ssRNA,IFN-β
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thways leading to the expression of antiviral effector genes upon virus infection.
the cytoplasmic sensors RIG-I or MDA5. Activation of these PRRs leads to the
e transcription of IFN genes as well as genes encoding ISGs and proinﬂammatory
hway, which leads to the formation of Stat1/2/IRF9 heterotrimers that translocate
suppresses HCV replication. Several HCV proteins counteract signaling molecules,
and NS5A may interfere with the JAK/STAT signaling pathway. ER, endoplasmatic
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respectively, appear to be the main sensors. They both reside in
endosomes and signal either via TRIF (TIR-domain-containing
adapter-inducing interferon-b) or MyD88 to activate IRF3/7 and
NFjB (Fig. 1). This ﬁnally leads to the production of proinﬂammo-
tory cytokines and chemokines (Fig. 1). Several lines of evidence
suggest that HCV is sensed by these TLRs. First, reconstitution of
TLR3 expression in HuH7 human hepatoma cells that normally do
not express TLR3 induces an antiviral state upon HCV infection
[31,32], which is likely enhanced by the TLR3-dependent tran-
scriptional upregulation of RIG-I (reviewed in [33,34]). Second,
a recent study reported dsRNA replication intermediates inducing
TLR3 signaling [32]. Third, by using the macrophage cell line
THP1, it was found that HCV RNA is sensed by TLR7 leading to
the expression of interleukin-1b (IL-1b), which is proposed to
be a central factor of liver inﬂammation [35]. Forth, it was shown
that HCV-infected cells activate IFN production by plasmacytoid
dendritic cells (pDCs) via TLR7 [36]. In summary, HCV is recog-
nized both by TLR3 and by TLR7, at least in cell cultures.Interferons and their role in controlling hepatitis C virus
Activation of the interferon response by hepatitis C virus
Based on receptor usage, IFNs are divided into three groups. Type
I IFNs comprise a multitude of cytokines with IFN-a and IFN-b
being the most important ones with respect to viral infections.
Type III IFNs comprise IFN-k1, IFN-k2, and IFN-k3 in humans (also
called IL-29, IL-28A and IL-28B, respectively). Moreover, a recent
study reported an additional open reading frame, which encodes
for IFN-k4 [4,37]. Type I and type III IFNs signal via the JAK-STAT
pathway (Fig. 1). However, they bind to different receptors that in
case of type III IFN is expressed mainly in epithelial cells and
hepatocytes (reviewed in [37]) whereas the type I IFN receptor
is expressed ubiquitously. Type II IFN comprises only IFN-c,
which is mainly produced by T cells and NK cells and acts on mul-
tiple cell types including immune cells.
Varying experimental systems such as cell culture models
[38–44], transgenic mice with human liver xenografts [45,46],
experimentally inoculated chimpanzees [11,47–52] and human
liver samples from HCV-infected patients [10–12,53] have been
used to characterize the IFN response induced by HCV. The com-
mon denominator is that HCV induces an upregulation of ISGs,
but the source of IFNs in the infected liver remains to be eluci-
dated. One likely source might be infected hepatocytes them-
selves, as inferred from the IFN production by PHHs infected
with HCV in vitro [11,54]. In addition, IFNs and other proinﬂam-
matory cytokines can be produced by resident or inﬁltrating
immune cells such as macrophages, Kupffer cells or DCs that
can be stimulated, e.g., by HCV RNA-containing exosomes
released from infected cells [55,56].
The pattern of ISGs detected in patients with chronic hepatitis
C clearly corresponds to a type I or III IFN signature [10,48,57].
Studies based on PHHs infected with cell culture-produced HCV,
or liver biopsies from infected patients and chimpanzees show
that the ISG expression pattern predominantly reﬂects a type I
and/or type III IFN response [48,51]. Moreover, several groups
reported upregulation of type III IFN in PHHs and in liver samples
from patients as well as experimentally infected chimpanzees
[11,38,49]. However, whether type I or type III IFN is the main
driver of HCV-induced ISG expression remains to be determined.Journal of Hepatology 2013Several single nucleotide polymorphisms (SNPs) have been
found in the IL28B gene locus, which seem to inﬂuence the
response to HCV [58–60]. The best studied SNPs do not reside in
the coding regionof the IL28A and IL28Bgenes, but rather upstream
(rs12979860, rs8099917) or downstream (rs12980275) of
IL28B (reviewed in [5]). Of note, the major genotype of SNP
rs12979860 (called C/C because of a homozygous cytosine at this
position) correlateswithbetter treatment response and viral clear-
ance [61–63]. However, the underlying mechanism is unknown
and appears to be independent of a global upregulation of ISGs
[64]. Moreover, non-responders have elevated ISG levels irrespec-
tive of the SNP genotype [65] arguing that IFN-k3, encoded by the
IL28B gene, does not directly control ISG induction.
More recently, a fourth SNP (ss469415590 (TT or DG)) was
found upstream of IL28B [4]. Interestingly, the DG variant is a
frameshift mutation creating a novel open reading frame, which
encodes for a protein that shares 40.8% amino acid sequence sim-
ilarity to IFN-k3 and hence has been designated IFN-k4 [4,37].
Overexpression of an engineered IFN-k4 fusion protein in a hep-
atoma cell line induced phosphorylation of STAT1 and STAT2,
expression of several ISGs, and suppression of HCV replication.
However, in spite of this antiviral activity, the presence of the
DG variant is in high disequilibrium with rs12979860 and corre-
lates with reduced response to IFN-a treatment as well as low
HCV clearance. Since overexpression of the engineered IFN-k4
protein was found to weakly pre-activate the IFN signaling path-
way, which prevented further activation by IFN-a or -k, it is
tempting to speculate that this refractoriness impairs HCV clear-
ance. Alternatively, methylation of a cysteine residue adjacent to
the DG variant might be important for HCV clearance [66].Interferon-stimulated genes and their impact on controlling
hepatitis C virus
More than300 ISGscanbeupregulatedby IFNs. For obvious reasons,
most transcriptomeproﬁles have been established byusing cell cul-
ture systems and only a limited number of proﬁles are available
from in vivo studies. In linewith the induction of ISGs by HCV infec-
tion itself enhanced transcription of ISGs in acutely and chronically
HCV-infected chimpanzees as well as chronically infected patients
has been observed. Importantly, the subsets of upregulated ISGs
detected in vivo overlap to a large degree with those detected in
IFN-treated cell cultures in in vitro [10,11,47,48,51,67,68]. Of note,
the spectrumof ISGs induced incultured cells in theabsenceorpres-
enceofHCVdoesnotdiffer, supporting thenotion thatHCVhas little
effect on the signaling cascade leading to ISG activation, at least
in vitro (M. Binder and R.B., unpublished).
In the absence of immuno-competent small animal models
that are fully permissive for HCV, no mechanistic in vivo evalua-
tion of speciﬁc ISGs is possible. Thus, our knowledge about the
mechanisms by which ISGs control HCV replication is based on
in vitro models. Below, we will ﬁrst summarize screens con-
ducted to identify ISGs that are involved in the control of HCV
and then focus on those ISGs for which insights into the underly-
ing mechanism are available.
Identiﬁcation of ISGs targeting hepatitis C virus
To identify genes responsible for the suppression of HCV replica-
tion in IFN-treated cells, several biased and unbiased screens
have been conducted in hepatoma cells. Identiﬁed ISGs restrict-vol. 59 j 1331–1341 1333
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Fig. 2. Phases of the HCV replication cycle and ISGs targeting these phases. Individual steps of the HCV replication cycle are given in the ﬁlled circles. These are virus
entry, RNA translation, replication of the plus-strand (+) RNA genome via a minus-strand copy (), assembly of infectious HCV particles that seems to require cytosolic lipid
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one step; ISGs marked in blue target multiple steps.
Reviewing or promoting HCV replication are summarized in Fig. 2 as well
as Tables 1 and 2, respectively, that also specify the used ISG
abbreviations.
A FACS-based phenotypic screen was used to determine the
antiviral activity of 389 ISGs upon overexpression in HuH7 and
HuH7.5 cells [25]. Lentivirus-based transduction was used to
introduce each ISG individually and transduced cells were
infected with an HCV reporter virus. A reduction of HCV-speciﬁc
signal in ISG-expressing cells indicated inhibition of viral replica-
tion. In this way, strongest antiviral effects were observed for
IRF1, RIG-I, MDA5, IRF2, and IRF7. While this result underscores
the important role of these RNA-sensing and key signaling mole-
cules in mounting an antiviral response against HCV, additional
ISGs were detected suppressing HCV replication to a much lesser1334 Journal of Hepatology 2013extent. These ISGs included DDIT4, NT5C3, IFI44L, MAP3K14, and
OASL (Table 1). It is likely that these factors exert a more direct
effect against HCV, e.g., by enhancing turnover of RNA or slowing
down RNA translation. The fact that none of these ISGs was suf-
ﬁcient to suppress HCV replication to an extent observed by IFN
treatment suggests that virus inhibition is brought about by the
concerted action of several ISGs.
In contrast to this overexpression approach, a whole-genome
RNA interference-based screen was performed by Zhao and
co-workers [69]. The authors used HuH7 cells containing a stably
replicating subgenomic HCV replicon and determined rescue of
viral replication by knockdown of a given gene with cells that
had been treated with IFN-a. With this approach, 93 genes were
identiﬁed contributing to suppression of HCV replication. Identi-vol. 59 j 1331–1341
Table 1. Interferon-stimulated genes described to restrict the HCV replication cycle.
ISG Abbreviation Cell system1 Infection or replicon- 
based test2
Test by over expression
or knock-down of ISG3
[Ref.]
ADAR1 HuH.BB7 rep kd [123]
DNA-damage-inducible transcript 4
Adenosine deaminase, RNA-specific
DDIT4 HuH7 inf/rep oe [25]
Guanylate binding protein 1 GBP-1 HuH7 rep oe/kd [44]
IFN alpha-inducible protein 27 IFI27 HuH7 rep oe/kd [44]
IFN induced protein 44-like IFI44L HuH7 inf/rep oe [25]
IFN alpha-inducible protein-16 IFI6-16 HuH7 rep oe/kd [44]
IFN induced protein with tetratricopeptide repeats 1 IFIT1 IHH inf oe/kd [41]
IFN induced protein with tetratricopeptide repeats 3 IFIT3 HuH7-Lunet rep kd [54]
IFN induced transmembrane protein 1 IFITM1 HuH7-Lunet rep kd [54]
IHH inf oe/kd [41]
HuH7 rep oe/kd [94]
IFN induced transmembrane protein 3 IFITM3 HuH7-Lunet rep oe/kd [54]
HuH7.5 rep oe [93]
HuH7 rep oe/kd [94]
IFN regulatory factor 1 IRF1 HuH7 inf/rep oe [25]
IFN regulatory factor 1 IRF1 HuH7 rep oe [44]
IFN regulatory factor 2 IRF2 HuH7 inf/rep oe [25]
IFN regulatory factor 7 IRF7 HuH7 inf/rep oe [25]
IFN regulatory factor 9 IRF9 HuH7 rep oe [44]
IFN stimulated gene 15 ISG15 HuH7 rep oe [122]
IFN stimulated gene 20 ISG20 HEK293 rep oe [101]
Mitogen-activated protein kinase kinase kinase 14 MAP3K14 HuH7 inf/rep oe [25]
Melanoma differentiation associated protein-5 MDA5 HuH7 inf/rep oe [25]
Myxovirus resistance protein A MxA HuH7 rep oe [44]
Nitric oxide synthase 2 NOS2 HuH7-Lunet rep oe/kd [54]
5’-Nucleotidase, cytosolic III NT5C3 HuH7 inf/rep oe [25]
2’-5’-Oligoadenylate synthetase OAS HuH7 rep oe [44]
2’-5’-Oligoadenylate synthetase 1 OAS1 HuH7 genome transf. oe [113]
2’-5’-Oligoadenylate synthetase 3 OAS3 HuH7 genome transf. oe [113]
2’-5’-Oligoadenylate synthetase-like OASL HuH7 inf oe [25]
HuH7 rep oe [110]
Protein kinase R PKR HuH7 rep oe/kd [44]
HEK293 rep oe [101]
HuH7 rep kd [124]
HuH7 rep oe/kd [94]
Phospholipid scramblase 1 PLSCR1 HuH7-Lunet rep oe/kd [54]
Retinoic acid inducible gene-I RIG-I HuH7 inf/rep oe [25]
Ribonuclease L RNASEL HuH7-Lunet rep oe/kd [54]
HuH7 inf oe [113]
Tetherin HuH7.5 inf oe [125]
Tripartite motif containing 14 TRIM14 HuH7-Lunet rep oe/kd [54]
Virus inhibitory protein, ER-Associated Viperin HEK293 rep oe [101]
HuH7 rep oe [68]
HuH7.5 inf/rep oe [104]
HuH7 inf kd [105]
1Cell line used for the study.
22ISGs were validated by using either infection of cells with HCV (inf) or subgenomic replicons (rep) or transfection of genomic in vitro transcripts (genome transf.).
3Antiviral effects were determined by using overexpression of a given ISG (oe) or by knockdown (kd) of the respective ISG in cells treated with IFN and measuring the
impact on HCV replication.
JOURNAL OF HEPATOLOGYﬁed hits were enriched for genes involved in IFN signaling, RNA
translation, and mRNA processing [69]. One of these genes, SART1,
was characterized in more detail. This factor was not induced by
IFN and reported to play a more general role in regulation of ISG
expression, which would explain its antiviral effect [69].Journal of Hepatology 2013By using an analogous ‘gain-of-function’ RNA interference-
based screen, Metz and co-workers identiﬁed 7 ISGs that rescue
HCV replication in IFN-a or IFN-c treated cells [54]. All of these
genes are induced by either IFN, showing a substantial overlap of
the ISG spectrum triggered by these cytokines. Nevertheless, somevol. 59 j 1331–1341 1335
Table 2. Interferon-stimulated genes described to promote the HCV replication cycle.
ISG Abbreviation Cell system1 Infection or replicon- 
based test2
Test by over expression
or knock down of ISG3
[Ref.]
IFN stimulated gene 15 ISG15 MH1 rep oe/kd [118]
HuH7.5 inf oe [119]
HuH7.25.
CD81
inf kd [84]
Protein kinase R
Ubiquitin specific peptidase 18
PKR HuH7.25.
CD81
inf kd [84]
HuH7 inf kd [83]
USP-18 HuH
1Cell line used for the study.
2 ISGs were validated by using either infection of cells with HCV (inf) or subgenomic replicons (rep).
3Antiviral effects were determined by using overexpression of a given ISG (oe) or by knockdown (kd) of the respective ISG in cells treated with IFN and measuring the
impact on HCV replication.
Reviewdifferences exist. For instance, phospholipid scramblase 1 and
inducible nitric oxide synthase 2 were identiﬁed as main effectors
of IFN-c. Similar to the results by Schoggins and co-workers [25], it
was found that the antiviral state blocking HCV replication
requires the combined activity of multiple ISGs [54].
Very recently, an unbiased genome-wide siRNA screen was
performed to identify ISGs as well as non-transcriptionally
induced genes required for the antiviral effect of IFN-a [70].
HuH7-derived cells were transfected with siRNAs and after
stimulation with IFN-a infected with HCV. By using an image-
based analysis, 9 genes were identiﬁed to be responsible for
IFN-a-mediated suppression of HCV replication (Table 1).
Furthermore, the individual contribution of each of these candi-
dates to inhibit distinct steps in the HCV replication cycle was
determined. Thereby, effector groups were identiﬁed targeting
viral entry, replication, RNA production or virus particle produc-
tion/release. Three of the candidates, MYST1, ALG10B, and PDIP1,
were found to target nearly all steps of the HCV life cycle. These
ﬁndings underscore that both ISGs and non-ISGs are required for
efﬁcient suppression of HCV.
In addition to the high-content screens described above, sev-
eral more targeted screens have been conducted. Although a
direct comparison of obtained results is ﬂawed by differences
of used experimental approaches, several ISGs have been identi-
ﬁed consistently. These include members of the IFITM family,
PKR, and viperin (Table 1).
Key Points
• Upon HCV infection of liver cells, the virus is 
recognized by cellular sensors leading to induction of
type I and III IFN. This induction is counteracted by the
NS3-4A protease. Whether other viral proteins also
impair IFN induction is contradictory
• Type I and III IFN production results in the upregulation
of a broad range of ISGs. Several of them suppress
HCV replication in a concerted action
• By and large, HCV is sensitive to the IFN-induced
antiviral state. This is exploited by currently used IFN-
based antiviral therapy
• It remains to be determined how HCV can persist in
presence of an IFN-induced antiviral state1336 Journal of Hepatology 2013Possible anti-hepatitis C virus mechanisms of selected ISGs7.5 inf kd [121]Protein kinase R
PKR is a central component that links pathogen sensing to stress
[71]. The kinase is a cytosolic sensor of viral dsRNA [72] and PKR
activation results in a global suppression of RNA translation and
thus, protein synthesis. Binding to dsRNA promotes PKR homodi-
merization and activates the kinase domain that phosphorylates
the alpha subunit of eukaryotic initiation factor 2 (eIF2a). This
factor is essential for initiation of cap-dependent mRNA transla-
tion and its phosphorylation blocks this process [73]. In addition,
translation arrest leads to the formation of complexes that are
composed of non-translated mRNAs and RNA-binding proteins
in so-called stress granules [74,75]. Apart from that, PKR links
pathogen sensing to metabolic homeostasis, virus-induced
autophagy [76], NF-jB signaling [77], and activation of the
inﬂammasome [78].
In vitro binding studies suggest that after HCV infection, PKR is
activated as a result of binding to distinct RNA structures in the
IRES residing in the 50 NTR of the genome [79]. However, the ben-
eﬁts and/or disadvantages of this activation for HCV replication
are controversial. PKR was initially recognized as an effector
ISG that is able to inhibit HCV replication [43,80]. Two viral pro-
teins, NS5A and E2, were reported as PKR inhibitors by direct
binding to the kinase. Comparison of genotype 1b full-length
virus sequences of IFN-a-responsive and non-responsive patients
suggested that HCV variants, unable to escape IFN antiviral
effects, accumulated mutations in the C-terminal region of
NS5A. This region was designated the IFN sensitivity determining
region (ISDR) [81]. Cell culture assays and in vitro studies suggest
that the ISDR overlaps with the PKR binding region in NS5A, argu-
ing that ISDR mutations might cause a loss of PKR binding and
thereby reduce susceptibility to IFN therapy [82]. This is an
attractive hypothesis, however, recent studies propose that PKR
acts as an HCV proviral rather than antiviral factor [54,83,84]. It
has been suggested that by activation of PKR, translation of ISG
mRNAs is attenuated without affecting translation of the HCV
genome that is mediated by the IRES and thus, eIF2a independent
[83,85]. While these results appear to be conﬂicting, it is possible
that activation and inhibition of PKR occur in a sequential man-
ner, with activation predominating at the early stage of infection
and inhibition of PKR at a later stage when high amounts of NS5A
have accumulated. However, how the reported enhancement ofvol. 59 j 1331–1341
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PKR autophosphorylation induced by interaction with the HCV
core protein ﬁts into this scenario remains to be determined [86].
NS5A is not the only viral protein assumed to interfere with
PKR. One study reported an inhibition by the viral envelope gly-
coprotein E2 via direct interaction with PKR [87]. Interestingly,
the interaction site in E2 was mapped to a highly conserved
amino acid sequence with high sequence homology to PKR auto-
phosphorylation and eIF2a phosphorylation sites. In addition, the
extent of sequence homology correlated with the IFN-resistance
phenotypes of different HCV genotypes [87]. Although this is an
elegant way to explain how HCV might block PKR, the physiolog-
ical relevance is not clear. In the study by Taylor and colleagues,
only E2 was used for expression-based interaction assays, even
though proper folding and membrane association of E2 require
co-expression with E1 [88]. Thus, these observations need to be
revisited by using more authentic viral proteins and adequate cell
culture systems.
To conclude, studies on inhibition or activation of PKR by HCV
are conﬂicting. This controversy is further emphasized by the dis-
crepant reports related to the effects that PKR silencing, inhibi-
tion or overexpression have on HCV replication that range from
inhibitory [84] to non-existent [25,54]. One obvious explanation
is the differences of used experimental conditions that are very
critical when analyzing rather subtle effects. One other source
of discrepancy is the multiple roles that PKR has in controlling
cell homeostasis, making experimental outcomes very dependent
on cell status. Thus, the role PKR plays in IFN-mediated suppres-
sion of HCV replication remains to be determined. We note that
in our hands neither silencing of PKR expression in IFN-a-treated
cells, nor PKR overexpression has an effect on HCV replication in
the commonly used cell line HuH7 [54].
Interferon-inducible transmembrane proteins
The IFITM family consists of 4 members: IFITM1, IFITM2, IFITM3,
and IFITM5. With the exception of the latter, all members are
ubiquitously expressed in humans and their expression is upreg-
ulated by all types of IFNs. IFITMs contain two anti-parallel trans-
membrane domains, a leucin-zipper motif, and a short
cytoplasmic domain. A membrane-proximal cysteine residue
can be modiﬁed post-translationally by S-palmitoylation control-
ling IFITM localisation in membrane compartments [89]. IFITM
proteins appear to counteract a wide range of viruses, but the
mode of action remains unclear [41,90–93]. In case of HCV,
IFITM1, and IFITM3 have been reported to interfere with viral
entry and RNA replication, respectively [41,54,93,94]. IFITM1 is
able to bind to two of the HCV co-receptors: the tetraspanin
CD81 and the tight junction protein occludin [94,95]. These co-
receptors have to interact with each other to enable virus particle
entry into hepatocytes. It is speculated that IFITM1, and to a
minor extent IFITM3, disrupt co-receptor interaction, thus inhib-
iting the entry process [94]. However, two alternative hypotheses
have been put forward. First, IFITMs might inhibit the fusion of
the viral envelope membrane with endosomes or lysosomes by
altering lipid components or blocking acidiﬁcation of virus-
containing endocytic vesicles. Second, IFITMs might alter vesicle
trafﬁcking in a way that the invading viruses are redirected to a
non-fusogenic pathway [92,96]. Apart from viral entry inhibition,
IFITM proteins also suppress HCV replication as deduced from
knockdown as well as overexpression studies [41,54,93]. Inter-
estingly, the combined knockdown of IFITM1 and IFITM3 has syn-Journal of Hepatology 2013ergistic effects arguing for a redundant antiviral mode-of-action
[54].
The mechanism of replication inhibition by IFITMs remains to
be determined. One study describes an interference of IFITM3
with HCV IRES-mediated RNA translation, however, this hypoth-
esis needs further proof as in this study also inhibition of cap-
dependent RNA translation was observed and a rather artiﬁcial
in vitro system based on extracts from HeLa cells has been used
[93]. Given the ‘membrane activity’ of IFITMs, it is much more
intuitive to speculate that IFITMs have a negative inﬂuence on
formation of the membranous web, which is the site of HCV
RNA replication. A recent study describes an inhibitory effect of
IFITM3 on cholesterol homeostasis [97]. Amongst others, choles-
terol synthesis is regulated by the vesicle-membrane-protein-
associated protein A (VAP-A) and oxysterol-binding protein
(OSBP). Interestingly, IFITM1, IFITM2, and IFITM3 can bind to
VAP-A and inhibit its interaction with OSBP. This results in cho-
lesterol-enriched multivesicular bodies and late endosomes that
inhibit release of several viruses into the cytosol. In the context
of HCV infection, the impact of IFITMs on cholesterol homeostasis
might have consequences on the formation of the membranous
web, which is a highly specialized membrane compartment that
contains high amounts of cholesterol [98]. Moreover, IFITM-med-
iated sequestration of VAP-A, which is an important cofactor for
efﬁcient HCV RNA replication, might contribute to this inhibitory
effect.
Viperin
Viperin (RSAD2) localizes to the ER and lipid droplets (LDs),
which are both important for HCV replication [99]. This protein
belongs to the radical S-adenosyl-L-methionine (SAM) superfam-
ily [100] that is characterized by a SAM domain, which is respon-
sible for methylation of nucleic acids and proteins. It was
speculated that SAM transferase activity is important for the anti-
viral activity of viperin [101]. However, mutagenesis studies
showed that not the SAM domain, but rather the N-terminal
amphipathic helix and the C-terminal region of the protein are
necessary for suppression of HCV replication [102]. The N-termi-
nal helix of viperin is responsible for its anchoring to the ER and
LDs [102]. Importantly, this helix inhibits protein secretion and
induces ER membrane curvature [103]. During HCV infection,
viperin resides in small cytoplasmic foci at the ER–LD interface.
These foci are thought to correspond to viral replication com-
plexes. It is thought that viperin interacts via its C-terminal
region with the core protein and NS5A that also localize to LDs
and LD-proximal ER membranes [102,104,105]. In addition,
viperin binds to VAP-A, an important host factor of HCV replica-
tion [104,105] that also regulates trafﬁcking and biogenesis of
lipids and sterols [106]. Therefore, one proposed mechanism of
viperin’s antiviral activity is the disintegration of the membra-
nous HCV replication compartment as a result of altered NS5A
– VAP-A interaction. This might cause an alteration of the lipid
composition of the membranous web thereby inhibiting HCV rep-
lication. Viperin has also been found to bind to and inhibit far-
nesyl diphosphate synthetase (FPPS) [107]. Like VAP-A, FPPS is
involved in the cholesterol and isoprenoid biosynthesis at the
ER membrane [108]. It is assumed that the inhibition of FPPS
by viperin may change the type or quantity of lipids in the ER
membrane and thus affect the composition of the ER-derived
HCV replication complex. Given the recent establishment of avol. 59 j 1331–1341 1337
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method to isolate functional membrane-associated HCV replica-
tion complexes, these attractive hypotheses can now be
addressed experimentally [98].
The oligoadenylate synthetase/ribonuclease L system
RNase L was one of the ﬁrst identiﬁed restriction factors of HCV
[109]. Subsequent studies could conﬁrm that the components of
this pathway are important for the counteraction of HCV infec-
tion [25,54,110]. RNase L contains 9 so-called ankyrin repeats
serving as protein-protein interaction platforms, several protein
kinase-like motifs, and a ribonuclease domain. This domain has
homology to IRE1 (inositol-requiring protein 1), an enzyme
important for the unfolded protein response (UPR) [111]. RNase
L is constitutively expressed in a wide range of tissues, but
requires stimulation of enzymatic activity by a particular oligo-
nucleotide (20,50-oligoadenylate) that is generated by the IFN-
inducible 2,5-linked oligoadenylate synthetases (OAS1, OAS3,
and OASL). Similar to PKR, OAS proteins require activation by
dsRNA that is generated during viral replication. Synthesized
20,50-oligoadenylate binds to RNase L to induce a conformational
change leading to its homodimerization and activation of the
endonuclease activity. RNase L cleaves viral as well as cellular
RNAs in single-stranded regions, mainly after UU or UA dinucle-
otides leaving a 50-OH and a 30-monophosphate [112]. This
unspeciﬁc cleavage counteracts several viral pathogens, including
HCV. Recent studies showed that all three OAS proteins induce
RNase L-dependent antiviral activity against HCV [25,110,113].
Some of the cleavage products of the HCV genome might serve
as ligands for RIG-I and MDA5 [114] thereby enhancing the
induction phase of the IFN pathway. Interestingly, HCV genomes
of less IFN-responsive genotypes (1a and 1b) have a lower fre-
quency of UA and UU dinucleotides as compared to genotypes
with higher IFN response (genotypes 2a, b and 3a, b) [109], indi-
cating that the OAS/RNase L system contributes to the control of
HCV replication also in vivo.
Interferon-stimulated gene 15
ISG15 is one of the most highly induced ISGs. It is a 15 kDa pro-
tein with two ubiquitin-like domains in the C- and N-terminal
region. Comparable to ubiquitin, ISG15 can be conjugated to
lysine residues of target proteins. This so-called ISGylation occurs
through the sequential reaction of an E1-activating, an E2-conju-
gating, and an E3 ligation enzyme. Mass spectrometry-based
studies identiﬁed more than 160 host proteins that are ISGylated,
including the important dsRNA sensors PKR and RIG-I [115].
ISGylation has two effects: ﬁrst, it alters protein property directly
by addition of ISG15; second, it reduces degradation of the target
protein by competing with ubiquitin conjugation [116]. In addi-
tion, ISG15 can be secreted and acts like a cytokine by modulating
immune responses such as activation of T cells and NK cells lead-
ing to the production of IFN-c [117].
Reports on the role of ISG15 in the HCV replication cycle are
controversial, but the majority of studies argue for a proviral
effect. For instance, ISG15 overexpression has been reported to
increase HCV replication while RNAi-mediated silencing of
ISG15 expression was found to inhibit HCV replication, albeit to
a rather low extent (2 to 3-fold) [118,119]. At the ﬁrst glance,
the proviral role of ISG15 appears counterintuitive, but it was
found that ISG15 overexpression inhibited induction of IFN-b1338 Journal of Hepatology 2013by HCV [120]. In line with this report, silencing of USP18 expres-
sion, which is a negative regulator of ISGylation, potentiates IFN-
a mediated HCV suppression [121]. These results suggest that
ISG15 counteracts the IFN-a response by ISGylation, e.g., of
important signaling factors, and this negative regulation is coun-
teracted by USP18 that removes ISG15 from target proteins.
Although this is a plausible assumption, one report seems to con-
tradict it. Kim and Yoo reported reduced HCV replication upon
overexpression of ISG15 or ISG15-conjugating enzymes [122].
This destabilization was blocked by a particular arginine for
lysine substitution in NS5A, arguing for an ISGylation-dependent
antiviral mechanism. However, these results have been obtained
in highly selected HCV replicon cell clones and thus, need to be
revisited in more authentic culture systems and by using replica-
tion-competent HCV isolates from different strains and geno-
types. We note that high hepatic ISG15 levels were found to
correlate with low antiviral IFN-response during the early phase
of antiviral therapy, supporting the notion that ISG15 is a nega-
tive regulator of the IFN system [118].
Conclusions
With the advent of HCV cell culture models, important insights
into the suppression of viral replication by the IFN-induced anti-
viral state have been gained. Nevertheless, several key questions
remain to be clariﬁed.
1. High-content screens have identiﬁed numerous ISGs that
might contribute to IFN-mediated control of HCV. However,
for a few of them we begin to understand the underlying
mechanism and for most of them, the mechanism is not
known.
2. A concerted action of multiple ISGs is responsible for the sup-
pression of HCV replication, but the relevant ISGs remain to be
identiﬁed. Determination of the ‘real’ ISG set will require sys-
tems that allow combination of multiple ISGs.
3. Given the frequent discrepancies reported for HCV-targeting
ISGs, more authentic cell culture systems as well as standard-
ization of used methods are urgently needed. Since many
results were obtained by using rather artiﬁcial experimental
systems, re-evaluations in more appropriate models are
required.
4. Validation of ISGs identiﬁed in cell culture or deduced from
analyses of patient samples in adequate in vivo models is nec-
essary. This will require a fully permissive and immuno-com-
petent mouse model, which is not yet available.Conﬂict of interest
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